Arbutus Biopharma (ABUS) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 218.9% versus a loss of 6.7%. Nuvectis Pharma is the larger company by market cap ($666.8 million vs $616.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | NVCT |
|---|---|---|
| Share price | $4.02 | $19.39 |
| Market cap | $616.24M | $666.80M |
| 1-day change | -1.23% | -2.27% |
| YTD return | -16.42% | +156.82% |
| 1-year return | -6.73% | +218.91% |
| 5-year return | +28.43% | — |
| P/E ratio (TTM) | 3.59 | — |
| EPS (TTM) | $1.12 | $-2.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.08M | — |
| Revenue growth (YoY) | +128.21% | — |
| Net income (latest FY) | $-33.50M | $-26.44M |
| Operating margin | -270.96% | — |
| Net margin | -237.88% | — |
| 52-week high | $5.45 | $29.28 |
| 52-week low | $3.50 | $5.77 |
| Distance from 52-week high | -26.24% | -33.77% |
| Analyst consensus | none | none |
| Avg. price target upside | +32.34% | +82.57% |
| Average volume | 4.98M | 206.37K |
| Shares outstanding | 153.29M | 34.39M |
| Employees | 19 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed ABUS by 225.6 percentage points over the past year.
About Arbutus Biopharma
ABUS stock →Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
ABUS vs NVCT FAQ
Which is bigger, Arbutus Biopharma or Nuvectis Pharma?
Nuvectis Pharma (NVCT) is larger, with a market capitalization of $666.80M compared with $616.24M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or NVCT?
NVCT returned +218.91% over the past 12 months, compared with -6.73% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Are Arbutus Biopharma and Nuvectis Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.